FMP
Enanta Pharmaceuticals, Inc.
ENTA
NASDAQ
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.
6.1 USD
-0.55 (-9.02%)
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
607.64M
892.25M
1.06B
1.31B
1.43B
1.78B
2.22B
2.76B
3.44B
4.29B
29.18M
-54.96M
-9.98M
299.08M
320.56M
153.13M
190.78M
237.68M
296.12M
368.92M
-3.19M
-13.06M
-23.82M
-7.34M
-14.92M
-20.82M
-25.94M
-32.31M
-40.26M
-50.16M
25.98M
-68.02M
-33.8M
291.74M
305.64M
132.31M
164.84M
205.37M
255.86M
318.76M
-
-
-
-
-
-
-
-
-
-
-